The Precision NanoSystems R&D team has demonstrated the development of a model mRNA-LNP therapeutic from discovery to scale-up production, with minimal formulation and process optimization. This case study offers a level review of data, methods and expertise on Lipid Nanoparticles (LNP) encapsulating an mRNA construct that expresses Erythropoietin (EPO) that was used to model the nanomedicine drug development process, from discovery, through pre-clinical development, to scale-up production of a candidate mRNA-LNP suitable for clinical testing.